NCT00492050View on ClinicalTrials.gov

Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

August 2, 2006

Primary Completion Date

February 28, 2021

Study Completion Date

June 28, 2026

Conditions
Waldenstrom's Macroglobulinemia
Interventions
DRUG

Bortezomib

1.6 mg/m\^2 IV Weekly on Days 1, 8, 15 and 22.

DRUG

Rituximab

375 mg/m\^2 IV on Day 8 and 22.

DRUG

Valacyclovir

500 mg orally daily (or acyclovir 200 mg orally twice daily)

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER